title: Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004.
abstract: In France, surveillance of anti-tuberculosis drug resistance is performed by the Azay-Mycobacteria network, representing 30% of all culture-positive cases. We sought to validate administrative and clinical data gathered by the network in 2004 and to produce corrected resistance rates accounting for the observed misclassification. We reviewed a 10% sample of patients' records diagnosed in 2004 and measured the agreement between controlled data and data collected by the network by using the kappa (kappa) statistic. A re-sampling bootstrap-based method was used to investigate the impact of bias found on resistance rates. Most of data collected by the network, such as demographic data, and country of birth had an excellent agreement (kappa>0.8) with controlled data. The concordance was good (kappa>0.6) for HIV status and tuberculosis site. The only variable slightly discordant with controlled data was prior history of treatment (kappa=0.52). However, after correcting crude resistance rates for the observed misclassification, all estimated rates were within confidence intervals based on reported rates. This validation study is in favour of a good quality of data produced by the network, even though corrected rates are slightly different from observed rates. Therefore, data collected through the network may be used for policy making and tuberculosis programme evaluation. However, improvement in data collection regarding prior history of treatment should be considered.
authors.affiliation: Université Pierre et Marie Curie, Paris 6, France.
authors.forename: P M
authors.initials: PM
authors.lastname: Khuê
authors.forename: A
authors.initials: A
authors.lastname: Mallet
authors.forename: N
authors.initials: N
authors.lastname: Veziris
authors.forename: V
authors.initials: V
authors.lastname: Jarlier
authors.forename: J
authors.initials: J
authors.lastname: Robert
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D018563:Disease Notification / Q000592:standards*; D024881:Drug Resistance, Bacterial; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011159:Population Surveillance / Q000379:methods*; D015995:Prevalence; D011785:Quality Assurance, Health Care; D012307:Risk Factors; D012494:Sampling Studies; D018709:Statistics, Nonparametric; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000995:Antitubercular Agents